EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Genetic Alteration Profiling in North Macedonian Lung Cancer Patients

Aleksandar Eftimov, Rubens Jovanovic, Slavica Kostadinova Kunovska iD, Magdalena Bogdanovska Todorovska iD, Boro Ilievski, Panche Zdravkovski, Selim Komina, Blagica Krstevska, Simonida Crvenkova iD, Marija Simonovska, Gordana Petrushevska iD

Genes · 2025

DOI: 10.3390/genes16101177 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Genes, 2025. Verfasst von Aleksandar Eftimov und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pathology, Faculty of Medicine, Ss. Cyril and Methodius University, 1000 Skopje, North Macedonia. Hauptthemen laut MEDLINE: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma. Die Arbeit nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Late diagnosis and inefficient treatment regimens lead to poor prognosis, with a low 5-year survival rate for both non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). New targeted therapeutic agents can be developed and introduced only by first discovering new driver oncogenes and with a thorough investigation of the known driver genes. The aim of the current study is to investigate the prevalence of alterations in the eight most frequently altered genes in lung cancer—BRAF, EGFR, KRAS, ALK, ROS1, HER2, PD-L1 and PIK3CA.

Methods

Real-time polymerase chain reaction (RT-PCR) was used to detect KRAS and EGFR mutations, multiplex PCR and microarray hybridization for KRAS/BRAF/PIK3CA mutations. Immunohistochemical analysis was performed for the detection of ALK, HER2/NEU, ROS-1 and PD-L1 alterations.

Results

Overall, 221/603 patients (36.65%) had at least one genetic alteration, of which 22 patients (3.65%) had two genetic alterations and two patients had more than two genetic alterations. Additionally, 50 patients were identified with one or more KRAS mutations (8.29%), 45 patients with EGFR mutations (7.46%), and 1.82% with PIK3CA mutations and 0.66% with BRAF mutations. Furthermore, 50% of the co-occurring alterations were either on KRAS and PIK3CA genes (3/6), on KRAS and BRAF genes (2/6, 33.33%) or on EGFR and PIK3CA genes (1/6, 16.67%), and 10.45% of the patients exhibited PD-L1 overexpression, 5.31% ALK rearrangements, and 2.36% HER2/NEU expression, with no ROS-1 rearrangements detected.

Conclusions

Comprehensive testing for somatic alterations in EGFR, BRAF, KRAS, and PIK3CA is significant in guiding therapeutic decisions in lung cancer management. Such testing should be routinely conducted to establish a thorough genetic profile of lung cancers in a manner that is both time-efficient and cost-effective.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsCarcinoma, Non-Small-Cell LungSmall Cell Lung CarcinomaHumansFemaleMaleMiddle AgedAgedMutationAdultClass I Phosphatidylinositol 3-KinasesProto-Oncogene Proteins p21(ras)Proto-Oncogene Proteins B-rafErbB ReceptorsAged, 80 and overBiomarkers, TumorB7-H1 AntigenAnaplastic Lymphoma KinaseErb-b2 Receptor Tyrosine Kinases

Stichwörter der Autor:innen

BRAFEGFRKRASgene alterationslung cancer

Substanzen

Class I Phosphatidylinositol 3-KinasesProto-Oncogene Proteins p21(ras)Proto-Oncogene Proteins B-rafErbB ReceptorsBiomarkers, TumorB7-H1 AntigenAnaplastic Lymphoma KinaseErb-b2 Receptor Tyrosine KinasesKRAS protein, humanPIK3CA protein, human

Autor:innen und Institutionen

  • Institute of Pathology, Faculty of Medicine, Ss. Cyril and Methodius University, 1000 Skopje, North Macedonia.
  • University Clinic of Radiotherapy and Oncology, Medical Faculty, 1000 Skopje, North Macedonia.

ORCID-Profile: Slavica Kostadinova Kunovska, Magdalena Bogdanovska Todorovska, Simonida Crvenkova, Gordana Petrushevska

Zitieren

APA

Eftimov, A., Jovanovic, R., Kostadinova Kunovska, S., Bogdanovska Todorovska, M., Ilievski, B., Zdravkovski, P., Komina, S., Krstevska, B., Crvenkova, S., Simonovska, M., & Petrushevska, G. (2025). Genetic Alteration Profiling in North Macedonian Lung Cancer Patients. Genes. https://doi.org/10.3390/genes16101177

Vancouver

Eftimov A, Jovanovic R, Kostadinova Kunovska S, Bogdanovska Todorovska M, Ilievski B, Zdravkovski P, et al. Genetic Alteration Profiling in North Macedonian Lung Cancer Patients. Genes. 2025. doi:10.3390/genes16101177

BibTeX
@article{Eftimov2025,
  author = {Eftimov, Aleksandar and Jovanovic, Rubens and Kostadinova Kunovska, Slavica and Bogdanovska Todorovska, Magdalena and Ilievski, Boro and Zdravkovski, Panche and Komina, Selim and Krstevska, Blagica and Crvenkova, Simonida and Simonovska, Marija and Petrushevska, Gordana},
  title = {Genetic Alteration Profiling in North Macedonian Lung Cancer Patients},
  journal = {Genes},
  year = {2025},
  doi = {10.3390/genes16101177}
}
Kostenlos starten →